Health
Yale Cancer Center Study Shows Immunotherapy Drug Combination Improves Response in HER2-Negative Breast Cancer Including a Subset of Estrogen Receptor Positive Cancers – Yale School of Medicine
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib…
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen…
Continue Reading
-
Noosa News9 hours agoSurgeon partner of former premier to testify over his patient’s death
-
General8 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General7 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Business6 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher